A systematic review of the cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitors in the treatment of cardiovascular diseases
SUN Ling-yao
WANG Wen-shan
WANG Xin-ru
YUAN Fang-zhe
GU Yu-qi
TAN Yu-jie
TIAN Lei
Abstract：Objective:To explore methodologies for the economic evaluation of proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors.Methods:A literature search was conducted from inception until January 15,2024,across PubMed,Embase,Scopus,Cochrane Library,and Web of Science databases to identify studies focusing on the economic aspects of PCSK9 inhibitors.The included studies were evaluated using the 2022 version of the Consolidated Health Economic Evaluation Reporting Standards(CHEERS).Results:Among 30 economic evaluation studies of PCSK9 inhibitors for the treatment of cardiovascular disease,27 utilized modeling for economic assessment,predominantly employing Markov models.These studies varied in terms of duration and health state quantities.In 23 studies,LDL-C reduction was extrapolated for efficacy assessment,while adverse drug reactions were not considered.Conclusion:The current literature mainly evaluates the economic value of drugs using Markov models,but there are limitations in the selection of drug efficacy indicators,and whether adverse drug reactions are included in the analysis.
Keywords：proprotein convertase subtilisin/kexin type 9 inhibitorscost-effectivenessmethodologysystematic review
Publication Date：2025-04-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 778-784 )